Horizon Therapeutics Q3 top-line up 90%, bottom-line up 172%; hikes FY20 guidance

• Horizon Therapeutics (NASDAQ:HZNP) Q3 results:
• Revenues: $636.4M (+89.7% Y/Y) vs consensus of $531.11M.
• Tepezza ((teprotumumab-trbw)) Q3 net sales of $286.9M.
• Orphan and Rheumatology Segment: Krystexxa: $108.5M (+9%); Ravicti: $64.6M (+8%); Procysbi: $43.1M (+7%); Actimmune: $28.3M (+2%); Buphenyl: $3.2M (+6%); Quinsair: $0.2M (-23%).
• Net income: $292.8M as compared to $18.2M prior year; income/share: $1.31 as compared to $0.09M prior year; non-GAAP Net Income: $392.2M (+216%); non-GAAP EPS: $1.74 (+172%) vs consensus of $0.97.
• Non-GAAP EBITDA: $329.8M (+153%).
• CF Ops: $108.9M.
• Cash and cash equivalents of $1.73B.
• 2020 Guidance: Revenues: $2.12B - 2.14B increased from $1.85B - 1.90B vs consensus of $1.95B; Non-GAAP EBITDA: $920M - 940M from $725M - 775M; Tepezza sales: >$800M from previous guidance of >$650M.
• https://seekingalpha.com/news/3629554-horizon-therapeutics-q3-top-line-up-90-and-bottom-line-up-172-raises-fy20-guidance